Patents Examined by Michelle S Horning
  • Modified virus-like particles of CMV
    Patent number: 11324836
    Abstract: The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: May 10, 2022
    Assignee: SAIBA AG
    Inventors: Martin Bachmann, Andris Zeltins, Paul Pumpens
  • Methods of producing and characterizing virus vaccine and virus vaccine composition
    Patent number: 11319529
    Abstract: This application pertains to methods of isolating virus particles and producing virus vaccine composition comprising subject a biological sample to an anion exchange chromatography and a hydroxyapatite chromatography. The application also pertains to rabies virus vaccine compositions and methods of assessing suitability of a virus vaccine composition or releasing a commercial batch of virus vaccine composition for clinical use.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: May 3, 2022
    Assignees: GUANGZHOU REALBENEFITSPOT PHARMACEUTICAL CO., LTD., GUANGZHOU YINHEYANGGUANG BIOLOGICS CO., LTD.
    Inventors: Dianlian Liu, Wen Ai, Mingfeng Shen
  • Assay for JC virus antibodies
    Patent number: 11287423
    Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: March 29, 2022
    Assignee: Biogen MA Inc.
    Inventors: Leonid Gorelik, Kenneth J. Simon, Meena Subramanyam, Mia Marie Rushe
  • Herpesvirus compositions and related methods
    Patent number: 11260123
    Abstract: The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable exctpients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compositions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: March 1, 2022
    Assignees: SANOFI PASTEUR LIMITED, SANOFI PASTEUR BIOLOGICS, LLC
    Inventors: Stephen Anderson, Simon Delagrave, John Hamberger, Qinglian Li, Sophia Mundle, Nausheen Rahman
  • Immunogenic influenza composition
    Patent number: 11260122
    Abstract: Methods for providing novel compositions useful as influenza immunogens are provided. The compositions enable a host response to immunogen sites normally not recognized by a host. The novel immunogens can be used as vaccines or to develop antibodies.
    Type: Grant
    Filed: May 12, 2019
    Date of Patent: March 1, 2022
    Assignee: Biological Mimetics, Inc.
    Inventors: Gregory J Tobin, Peter L Nara, George Lin
  • Use of MVA or MVA?E3L as immunotherapeutic agents against solid tumors
    Patent number: 11253560
    Abstract: The present disclosure relates to modified vaccinia Ankara (MVA) virus or MVA?E3L delivered intratumorally or systemically as an anticancer immunotherapeutic agent, alone, or in combination with one or more immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to mobilizing the host's immune system to mount an immune response against the tumor.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: February 22, 2022
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Liang Deng, Jedd Wolchok, Taha Merghoub, Stewart Shuman, Peihong Dai, Weiyi Wang
  • Therapeutic bacteriophage compositions
    Patent number: 11253557
    Abstract: The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages selected from Sa87, J-Sa36, Sa83, J-Sa37, or mutants thereof, use of the same for medical or non-medical applications, kits, bandage, and wound dressing comprising the same.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: February 22, 2022
    Assignee: ARMATA PHARMACEUTICALS, INC.
    Inventors: Karen Joy Shaw, Sandra P. Morales, Gillian Mearns, Deborah A. Rankin, Frenk Smrekar
  • Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
    Patent number: 11246928
    Abstract: Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that hind near the HA0 maturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: February 15, 2022
    Assignees: CONTRAFECT CORPORATION, TRELLIS BIOSCIENCE, LLC
    Inventors: Angeles Estelles, Lawrence M. Kauvar, Adam Vigil, Michael Wittekind
  • Compositions and methods for treatment of cytomegalovirus
    Patent number: 11248026
    Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: February 15, 2022
    Assignees: Variation Biotechnologies Inc., Sorbonne Université
    Inventors: David E. Anderson, Anne-Catherine Fluckiger, David Klatzmann, Charlotte Dalba-Fribert
  • Nepovirus coat protein fusion polypeptides and their use
    Patent number: 11236132
    Abstract: The present invention relates to novel fusion polypeptides and the uses thereof. The invention particularly relates to conjugated coat proteins derived from nepoviruses, virus-like particles made with such proteins, and the uses thereof. The particles of the invention can expose and/or encage molecules of interest and have utility in various fields such as the pharmaceutical, agro, or veterinary areas.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: February 1, 2022
    Assignees: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Lorène Belval, Gérard Demangeat, Caroline Hemmer, Christophe Ritzenthaler
  • Recombinant non-pathogenic Marek's Disease virus constructs encoding multiple heterologous antigens
    Patent number: 11229698
    Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express foreign antigens from three or more avian viruses, along with methods of the use of the multivalent poultry virus vaccines.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: January 25, 2022
    Assignee: Intervet Inc.
    Inventors: Stephanie M. Cook, Mohamad Morsey, Ian Tarpey
  • Constructs for enhancing immune responses
    Patent number: 11207402
    Abstract: Chimeric protein constructs including a herpesvirus glycoprotein D (gD) and a heterologous polypeptide that interact with herpes virus entry mediator (HVEM) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: December 28, 2021
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Hildegund C. J. Ertl, Marcio O. Lasaro, Luis C. S. Ferreira
  • Liquid pharmaceutical composition
    Patent number: 11197930
    Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: December 14, 2021
    Assignee: Fresenius Kabi Deustschland GmbH
    Inventors: Gianluca Rinaldi, Silvia Fratarcangeli, Alessandra Del Rio
  • Viral nanoparticle multimers
    Patent number: 11193111
    Abstract: Virus particle multimers and methods of making and using such virus particle multimer are described. Virus particle multimers are constructed by preparing a plurality of asymmetrically functionalized virus particles bearing one or more functional groups and contacting the asymmetrically functionalized virus particles with a first linker molecule that reacts with the functional groups to form a virus particle multimer that includes a plurality of asymmetrically functionalized virus particles connected by the linker molecule. The asymmetrically functionalized virus particles are typically prepared by attaching the virus particles to a support surface to allow asymmetrical functionalization to be introduced.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: December 7, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Nicole F. Steinmetz, Amy M. Wen
  • Hepatitis C virus E1/E2 heterodimers and methods of producing same
    Patent number: 11186615
    Abstract: The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) E1 polypeptide and an HCV E2 polypeptide, where one or both of the E1 and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1/E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1/E2 heterodimers. The present disclosure provides HCV E1/E2 heterodimers, compositions comprising same, and methods of inducing an immune response to HCV.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: November 30, 2021
    Assignee: The Governors of the University of Alberta
    Inventors: Michael Houghton, Darren Hockman, John L. Law, Chao Chen, Michael Logan
  • Phage wrapping
    Patent number: 11168306
    Abstract: Disclosed herein, inter alia, are compositions and methods useful for improving detection of analytes. The compositions and methods provided include polymer-wrapped viral particles useful, inter alia, for the detection of PSMA.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: November 9, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Gregory A. Weiss, Kritika Mohan, Lindsay Kindra, Reginald M. Penner
  • Immunoglobulin chimeric monomer-dimer hybrids
    Patent number: 11168125
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: November 9, 2021
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
  • Genetically attenuated nucleic acid vaccine
    Patent number: 11154607
    Abstract: The disclosed compositions and methods provide an approach for the rational development of a nucleic acid vaccine. Methods are disclosed to deliver a viral genome, and/or a representative or derivative of such, that is attenuated but can, when co-delivered with unreplicable compensatory translational tools to a host cell, initially generate phenotypically wild-type, genetically attenuated viruses which infect subsequent cells and elicit a relevant and robust immune response. However, progeny of this initial generation, lacking the compensatory tools delivered to the initial host cells, are both phenotypically and genetically attenuated, thereby compromised in their ability to induce disease.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: October 26, 2021
    Inventors: Laura Shackelton, Matthew Kerner
  • Method for producing virus like particles
    Patent number: 11154614
    Abstract: The present invention relates to the production of structural proteins and virus-like particles (VLPs) of flaviviruses and hepatitis C. Production is through use of a single expression cassette comprising a viral structural gene, a furin encoding gene and a bicistronic expression element such as an internal ribosome entry site (IRES) between the viral and furin genes. Both the viral gene and furin gene can include a partial capsid encoding sequence acting as a signal peptide to co-locate the viral protein and furin and to act as a membrane anchor for the viral protein and furin. A separate expression cassette comprising a non-structural viral gene can be combined with the initial cassette. The structural proteins and VLPs can be used in vaccines and in the treatment of viral infections.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: October 26, 2021
    Assignee: INTEGRATED RESEARCH ASSOCIATES, LLC
    Inventors: Mary Jane Cardosa, Katharine Bossart
  • Herpes simplex virus nanoemulsion vaccine
    Patent number: 11147869
    Abstract: The present application relates to the field of human immunology, in particular, a herpes simplex virus (HSV) vaccine. The subunit vaccine composition comprises isolated surface glycoproteins from herpes simplex viruses, fusion proteins or fragments thereof mixed in varied combination with a nanoemulsion, which is a potent immune enhancer.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: October 19, 2021
    Assignee: BlueWillow Biologics, Inc.
    Inventors: Ali I. Fattom, Jakub Simon, James R. Baker, Jr., Tarek Hamouda, Vira Bitko